Zacks small cap research.

Apr 10, 2023 · RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial. When you start getting deeper into the world of investing, you’ll begin learning an entirely new, finance-specific vocabulary. From assets and mutual funds to expense ratios and the New York Stock Exchange, there’s certainly a lot to absorb...By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinuedJohn Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...

David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...Zacks Small Cap Research. TENX: Prioritizing Levosimendan. Read full article. Zacks Small Cap Research. May 22, 2023 at 6:44 AM ...

2 days ago · This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ...

LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier.May 23, 2023 · A date for the Adcom has not been announced yet. This news follows the company’s Type A meeting with the FDA in early January 2023 to discuss the refusal to file letter (RTF) that the company received in November 2022. The RTF letter made the BLA inactive and the FDA offered multiple options for BrainStorm to pursue to re-activate the BLA. By David Bautz, PhD. NASDAQ:MDNA. READ THE FULL MDNA RESEARCH REPORT. Business Update. Update on ABILITY Trial. Medicenna Therapeutics Corp. (NASDAQ:MDNA) is currently conducting the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid …Zacks Small-Cap Research Sponsored – Impartial - Comprehensive November 16, 2023 David Bautz, PhD 312-265-9471 [email protected] Sponsored – Impartial - …Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.

5 Small Cap Value Stocks to Keep on Your Watch List. 1. Caleres (. CAL Quick Quote. CAL - Free Report) is a specialty retailer with over 1000 retail locations in 68 countries. Its brands include ...

Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.

By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT Uxin Limited (NASDAQ:UXIN) operates a leading e-commerce platform for buying and selling used cars in China. The company also has two physical locations where customers can view and purchase cars in person. The company has recently transitioned …Zacks Small Cap Research. TENX: Notice of Allowance Increases Confidence. Read full article. Zacks Small Cap Research. June 23, 2023 at 3:24 AM ...On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)Oct 17, 2022 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT Uxin Limited (NASDAQ:UXIN) operates a leading e-commerce platform for buying and selling used cars in China. The company also has two physical locations where customers can view and purchase cars in person. The company has recently transitioned to an inventory-owning model which provides customers with a comprehensive transaction Mar 23, 2023 · By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent with the filing of Form 20-F. A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update in November include

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...In a March 28, 2023 press release, Allarity announced updates to its Phase II programs that are evaluating Ixempra and stenoparib as monotherapies. The pace of recruitment for both trials has been slow due to impacts from the pandemic and from on-site personnel staffing. To address the issue, Allarity has engaged additional contract research ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Oct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ... Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ...

On March 10, 2022 Lipocine filed its 2022 Form 10-K and posted its earnings release for the year ending December 31, 2022. Highlights for 2022 and to-date include: TLANDO approved – March 2022. LPCN 1144 end of Phase II meeting with FDA – July 2022. LPCN 2101 IND cleared – July 2022.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

May 22, 2023 · By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ... Sep 29, 2023 · By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial.Thermon Holding has a market cap of $669.2 million and a VGM Score of A. The Zacks Consensus Estimate for its current-year and 2023 earnings has improved 19.4% and 12.6% over the past 30 days to ...By John Vandermosten, CFA. NYSE:NHWK. READ THE FULL NHWK RESEARCH REPORT. The recently renamed NightHawk Biosciences, Inc. (NYSE:NHWK) reported first quarter 2022 results on May 16, 2022 and filed its Form 10-Q with the SEC. It has been a whirlwind year for the company as it made an acquisition, expanded its …Zacks Small-Cap Research Sponsored – Impartial – Comprehensive October 9, 2023 John D. Vandermosten, CFA 312-265-9588 / [email protected] scr.zacks.com 10 S. …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA.Aug 1, 2023 · read the full nexcf research report Nextech (OTC:NEXCF) preannounced Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. It expects gross margins to be the same as in Q1 at 38%.

Nov 14, 2023 · CBAK Energy Technology (NASDAQ:CBAT) reports impressive third-quarter revenues as the energy storage market remains strong. • Revenues grew sharply jumping 9.9% year over year and 49.6% sequentially to $63.4 million • More importantly battery revenues grew to $44.3 million up $18.5 million or 71 ...

Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 Year

Knowing which ridge cap you can use for an architectural roof, and which you should not is vitally important to the longevity of the roof. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest ...Zacks Rank N/A Obtaining Capital Zacks Small-Cap Research Sponsored – Impartial – Comprehensive 312 scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 February 14, 2023 John D. Vandermosten, CFA -265 9588 / [email protected] ESTIMATES Revenue Q1 Q2 Q3 Q4 YearEarnings Update. • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon “satisfaction ...By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update IGALMI™ Approved by the FDA On April 6, 2022, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that the U.S ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Aug 24, 2021 · By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Phase 1 Trial of EPI-7386 ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen A conference call with investors and analysts was held immediately following the release. 2Q:23 revenues of $3.6 million were ahead of our initial estimates and matched revised company guidance. Net loss per share was ($1.03). Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023.Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 YearZacks Small Cap Research. UXIN: Uxin reports strong year over year growth in vehicle units sold. Read full article. Zacks Small Cap Research. August 17, 2023 at 1:10 PM ...Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.Oct 31, 2023 · $31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three... The Morningstar US Small Cap Extended Index comprises of small-capitalization U.S. equities. The ETF return is roughly 10.19% so far this year and is up …

Earnings Update. • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon “satisfaction ...Brian Lantier, CFA is a Senior Research Analyst with Zacks Small-Cap Research covering technology, software, consumer internet and special situations. Brian has over 20 years of equity research experience. Brian began his career as a member of the small cap growth team at Lehman Brothers where his coverage universe included software, satellites ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...Instagram:https://instagram. invest in art stockscorient capital partnerswhere can you buy futureshow can i invest in startups SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Sep 29, 2023 · By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184. mortgage backed bondsstock calculator dividend By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view. norwegian cruise lines stock price The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a …A cap is an award given to a soccer player who represents his country in international matches. Each time a player participates in an international match, he is “capped.” Many soccer players have been capped, and several have reached 100 or...